Skip to main navigation Skip to search Skip to main content

PUM1 mediates the posttranscriptional regulation of human fetal hemoglobin

  • Reem Elagooz
  • , Anita R. Dhara
  • , Rose M. Gott
  • , Sarah E. Adams
  • , Rachael A. White
  • , Arnab Ghosh
  • , Shinjini Ganguly
  • , Yuncheng Man
  • , Amma Owusu-Ansah
  • , Omar Y. Mian
  • , Umut A. Gurkan
  • , Anton A A Komar
  • , Mahesh Ramamoorthy
  • , Merli N Gnanapragasam
  • Cleveland State University
  • Taussig Cancer Center
  • Rainbow Babies & Children’s Hospital
  • Department of Biomedical Engineering
  • Cleveland Clinic Foundation
  • Case Western Reserve University

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

The fetal-to-adult hemoglobin switching at about the time of birth involves a shift in expression from γ-globin to β-globin in erythroid cells. Effective re-expression of fetal γ-globin can ameliorate sickle cell anemia and β-thalassemia. Despite the physiological and clinical relevance of this switch, its posttranscriptional regulation is poorly understood. Here, we identify Pumilo 1 (PUM1), an RNA-binding protein with no previously reported functions in erythropoiesis, as a direct posttranscriptional regulator of β-globin switching. PUM1, whose expression is regulated by the erythroid master transcription factor erythroid Krüppel-like factor (EKLF/KLF1), peaks during erythroid differentiation, binds γ-globin messenger RNA (mRNA), and reduces γ-globin (HBG1) mRNA stability and translational efficiency, which culminates in reduced γ-globin protein levels. Knockdown of PUM1 leads to a robust increase in fetal hemoglobin (~22% HbF) without affecting β-globin levels in human erythroid cells. Importantly, targeting PUM1 does not limit the progression of erythropoiesis, which provides a potentially safe and effective treatment strategy for sickle cell anemia and β-thalassemia. In support of this idea, we report elevated levels of HbF in the absence of anemia in an individual with a novel heterozygous PUM1 mutation in the RNA-binding domain (p.(His1090Profs*16); c.3267_3270delTCAC), which suggests that PUM1-mediated posttranscriptional regulation is a critical player during human hemoglobin switching.
Original languageEnglish
Pages (from-to)6016-6022
Number of pages7
JournalBlood Advances
Volume6
Issue number23
DOIs
StatePublished - Dec 13 2022

Cite this